What Are Peptides and How Do They Work?

Quick answer:

Peptides are short chains of amino acids, the same building blocks that make up proteins. Your body already produces thousands of them and uses them as messengers: signals that tell specific cells to do specific things like release a hormone, repair tissue, or regulate appetite. Synthetic peptides work the same way, but are made in a laboratory to target specific processes more precisely or to last longer in the body.

Peptides are everywhere right now and for good reason.

Ozempic and Mounjaro went mainstream as weight loss treatments, and suddenly millions of people realised that a peptide injection could produce results that decades of dieting could not. Then Joe Rogan talked about BPC-157 to his audience of millions. Then TikTok filled up with before-and-after videos. Demand shifted overnight.

At the same time, a significant grey market developed. Research peptides compounds not licensed as medicines but legal to sell for research purposes became widely available in the UK, with communities on Reddit, Telegram, and Discord sharing protocols and sourcing advice faster than any medical journal could keep up.

The result is a space full of genuine science, genuine results, and genuine confusion. Most content online is either too vague to be useful or so technical it loses you by the second paragraph.

This guide sits in the middle. By the end, you will understand exactly what peptides are, how they work inside your body, what separates MHRA-approved medicines from research compounds, how peptides are actually manufactured, and what all of this means in practice for anyone curious about peptides in the UK.

What Exactly Is a Peptide?

At its most basic, a peptide is a short chain of amino acids the same building blocks that make up proteins. The difference between a peptide and a protein is simply length.

Think of amino acids as individual Lego bricks. A peptide is a short, purposeful structure built from a handful of those bricks. A protein is a full Lego city. Two to fifty amino acids joined together is a peptide. More than that and you are looking at a protein.

Your body is already producing thousands of peptides right now. Some you will recognise immediately:

Insulin the peptide that regulates your blood sugar
Oxytocin the bonding peptide released when you hug someone
Glucagon the peptide that tells your liver to release sugar when blood sugar drops
Endorphins the peptides your brain releases during exercise that reduce pain and lift mood
GLP-1 the gut peptide that tells your brain you are full after eating

These are not exotic foreign substances. They are molecules your body already knows and uses every single day.

What makes peptides so scientifically interesting is their role as signalling molecules the body’s messaging system. A peptide is essentially a chemical text message sent to a specific cell with a specific instruction. Heal this tissue. Release this hormone. Reduce this inflammation. Build this collagen. That precision is what makes peptides so different from older, broader-acting drugs.

A Brief History of Peptides: From 1902 to Today

Understanding where peptides came from helps explain why there are now two very different worlds pharmaceutical medicines and research compounds and why both exist legitimately.

The story begins in 1902, when two British physiologists, Ernest Starling and William Bayliss, discovered a substance they called secretin. When acid from the stomach arrived in the small intestine, the intestinal wall released a chemical messenger into the bloodstream that travelled to the pancreas and told it to produce digestive juices. This was the first time a peptide had been identified though the word did not exist yet. Starling later coined the term “hormone” to describe these messengers.

The real breakthrough came in 1921, when Canadian scientist Frederick Banting and his assistant Charles Best isolated insulin from the pancreas of dogs. Within a year, a fourteen-year-old boy named Leonard Thompson dying from diabetes became the first human to receive an insulin injection. He recovered. Insulin went from discovery to life-saving treatment in under twelve months. It remains one of the fastest medical breakthroughs in history and launched the entire field of peptide therapeutics.

In 1953, chemist Vincent du Vigneaud did something remarkable: he synthesised oxytocin from scratch in a laboratory. For the first time, humans had built a naturally occurring peptide rather than extracting it from animal tissue. He was awarded the Nobel Prize in Chemistry in 1955. This proved that synthesis not just extraction was possible, and opened the door to everything that followed.

Then in 1963 came the most important technological leap in peptide history. Robert Bruce Merrifield introduced solid-phase peptide synthesis (SPPS) a method of assembling amino acids one by one onto a solid resin, like building a chain link by link. It was automatable, repeatable, and dramatically faster than anything before it. Merrifield won the Nobel Prize in Chemistry in 1984. Without SPPS, most of the peptides discussed in research and fitness communities today would not exist at accessible prices.

Through the 1970s and 1980s, researchers discovered neuropeptides peptides acting in the brain and nervous system. Endorphins, enkephalins, substance P. The 1990s and 2000s brought biotechnology that allowed bacteria and yeast to be engineered to produce peptides at massive scale, which is why insulin today costs a fraction of what it did fifty years ago.

And then came the era we are in now. The 2010s and 2020s brought an explosion in peptide research driven by better synthesis technology, cheaper analytical tools, and an internet that allows researchers, clinicians, and communities to share findings faster than the scientific establishment can respond.

By the numbers: As of 2019, over 80 peptide drugs were approved worldwide across diabetes, cancer, osteoporosis, HIV, and chronic pain. Global peptide drug sales exceeded $70 billion in 2019, more than double the figure from 2013. The GLP-1 receptor agonists alone the family that includes Ozempic, Mounjaro, and Retatrutide, are projected to become the biggest-selling pharmaceutical category in history. (Source:Signal Transduction and Targeted Therapy, 2022)

How Do Peptides Work in the Body?

Here is the simplest way to understand how peptides work: a lock and a key.

Every cell in your body has receptors on its surface, think of these as locks. Each peptide has a specific shape, think of that as a key. When the right peptide meets the right receptor, it fits perfectly and triggers a response inside the cell.

That response is a signal. The cell receives the message and changes its behaviour accordingly. Here is how it unfolds:

The peptide reaches its target cell through the bloodstream, tissue, or skin
It binds to a receptor on the cell’s surface, and the key turns in the lock
The receptor sends a signal inside the cell a chain reaction begins
The cell changes what it is doing, releasing a hormone, producing collagen, repairing tissue, and reducing inflammation
The peptide breaks down, enzymes dismantle it back into amino acids, which the body recycles

That last step is important. Peptides do not linger indefinitely. Most have short lifespans in the body, which is why dosing frequency and delivery method matter so much in practice.

It’s a fact that a peptide only fits the receptors it was designed for, which is what makes peptides fundamentally different from many conventional drugs. A GLP-1 receptor agonist acts on GLP-1 receptors in the gut, pancreas, and brain. It does not randomly activate receptors in your joints or your skin. That targeted action is why approved peptide medicines have produced results that broader-acting approaches could not match.

MHRA-Approved Peptides vs Research Peptides

Not all peptides are the same from a regulatory standpoint, and understanding this distinction is essential for anyone exploring peptides in the UK.

MHRA-Approved Peptide Medicines

Some peptides have completed the full clinical trial process and received approval from the MHRA (Medicines and Healthcare products Regulatory Agency), the UK’s equivalent of the FDA. These are licensed medicines. They have been tested for safety and efficacy in large-scale human trials, manufactured under strict pharmaceutical-grade conditions, and can be legally prescribed by doctors and dispensed through pharmacies.

Well-known examples include:

Semaglutide (Ozempic, Wegovy) – GLP-1 receptor agonist for type 2 diabetes and weight management
Tirzepatide (Mounjaro) – dual GIP/GLP-1 receptor agonist for weight management
Liraglutide (Saxenda, Victoza) – GLP-1 receptor agonist for weight management and diabetes
Insulin – the original peptide medicine, in clinical use since 1923

These medicines come with well-documented side effect profiles, established dosing protocols, and clear eligibility criteria in the UK through NHS or private prescription routes.

Research Peptides

Research peptides occupy a different category. These are compounds that have not completed the clinical trial process required for MHRA licensing as human medicines. They are legal to sell in the UK for research purposes only; they cannot be legally marketed with therapeutic or health claims.

This does not mean they are dangerous or ineffective. It means the formal human evidence required for a medicine licence does not yet exist. Many research peptides have extensive preclinical data from animal studies, and some have early-phase human research behind them. The evidence base is developing it is simply not at the standard required for a medicine licence.

Widely discussed research peptides in the UK include:

BPC-157 studied for tissue repair, tendon healing, and gut health
TB-500 (Thymosin Beta-4) studied for muscle and connective tissue recovery
Ipamorelin / CJC-1295 growth hormone secretagogues studied for body composition and recovery
GHK-Cu copper peptide studied for skin repair and collagen production
Epithalon studied in the context of longevity and cellular ageing

The practical distinction is this: MHRA-approved peptides come with a prescription, a pharmacist, and a clinically established protocol. Research peptides require the user to do their own due diligence on sourcing, purity, and the strength of the evidence behind the compound they are considering.

Who Makes Peptides and How Are They Manufactured?

Understanding the supply chain and manufacturing process is not abstract chemistry it directly affects the quality and purity of what ends up in a vial.

The Four-Tier Supply Chain

Tier 1 Big Pharma: Companies like Novo Nordisk (semaglutide), Eli Lilly (tirzepatide), and AstraZeneca produce MHRA-licensed peptide medicines at pharmaceutical grade. Full clinical trials, regulatory approval, tightly controlled manufacturing. Their products are patented and sold legally through pharmacies.

Tier 2 Research Chemical Companies: Companies like Peptide Sciences and Bachem synthesise peptides at research grade typically 98% purity or above for sale to laboratories and researchers. They operate legally by selling for research purposes only and making no human-use claims.

Tier 3 Asian Manufacturers: The majority of research peptides sold globally originate from manufacturers in China and India primarily in Shenzhen, Shanghai, and Chengdu. The quality spectrum is broad. Some facilities operate at genuine pharmaceutical-grade GMP standards with ISO certification. Others have far less rigorous quality controls. The challenge is that from the outside, a certificate of analysis from either type of facility can look identical.

Tier 4 UK/EU Resellers: These companies import from Tier 2 or Tier 3 manufacturers, test the product, and resell under their own brand. Some conduct rigorous independent testing. Others do not. Knowing which is which is a core part of sourcing safely.

How Research Peptides Are Made: SPPS

Modern research peptides are manufactured using solid-phase peptide synthesis (SPPS) the same foundational chemistry Merrifield developed in 1963, now highly automated.

The process starts with a solid resin bead acting as an anchor. Amino acids are added one at a time in the correct sequence, each chemically bonded to the previous one. Between each addition, the resin is washed to remove unreacted material and byproducts. Once the full sequence is assembled, the peptide chain is cleaved from the resin using a chemical reagent and collected as a crude mixture.

That crude mixture contains more than just the target peptide shorter incomplete sequences, incorrectly assembled variants, and chemical residues are all present. This is why purification is essential, not optional.

Purification is carried out using high-performance liquid chromatography (HPLC), which separates the target peptide from contaminants. A well-executed HPLC purification achieves purity of 98% or above. This figure the one you look for on a Certificate of Analysis tells you whether the synthesis and purification were done properly.

Lyophilisation is the final step. The purified peptide solution is freeze-dried, removing all water and solvents while preserving the molecular structure. The result is the fine white or off-white powder you see in sealed vials. This form is chemically stable for extended periods when stored correctly far more stable than a pre-mixed solution, which begins degrading as soon as water is added.

Why a COA Matters

A Certificate of Analysis (COA) from an independent third-party laboratory is the only reliable way to verify the quality of a research peptide. It should confirm identity (that the peptide is what it claims to be), purity (ideally 98%+ by HPLC), and absence of harmful contaminants. A COA from the manufacturer’s own facility is significantly less reliable than one from an independent laboratory the two can look identical on paper but carry very different weight.

What Do Peptides Actually Do? Real-World Examples

Now that you understand the mechanism and the supply chain, here is what different types of peptides are actually used for.

Weight Management

The GLP-1 receptor agonists semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and the emerging retatrutide work by mimicking the gut hormone GLP-1 that your body naturally releases after eating. They reduce appetite, slow gastric emptying, and improve blood sugar regulation. Clinical trials have shown average weight loss of 15 to 20%+ of body weight over 68 weeks, which is why these compounds have transformed the obesity treatment landscape. These are MHRA-licensed medicines in the UK.

Muscle Recovery and Repair

BPC-157 and TB-500 are the two most widely discussed research peptides in UK fitness and sports communities. BPC-157 is studied for its potential role in tendon, ligament, and gut tissue healing. TB-500 is a synthetic analogue of thymosin beta-4, a naturally occurring protein involved in how cells migrate and repair tissue. Both are preclinical their evidence base comes largely from animal studies, with no completed large-scale human trials.

Anti-Ageing and Longevity

GHK-Cu is a copper peptide that occurs naturally in blood plasma and declines with age. It signals skin fibroblasts to produce collagen and elastin, and has a growing topical evidence base. Epithalon is a synthetic tetrapeptide studied in the context of telomere length and longevity. Both sit in the research category neither is an MHRA-licensed medicine.

Growth Hormone

Ipamorelin and CJC-1295 are growth hormone secretagogues they signal the pituitary gland to produce more of your own growth hormone in its natural pulsatile rhythm, rather than introducing synthetic growth hormone directly. They are widely researched for body composition, recovery, and sleep quality. Both are research peptides in the UK, and both are on the UKAD prohibited list for competitive athletes.

Why Delivery Method Matters

One of the most common questions around peptides is why so many require injection rather than being taken as a tablet. The answer is straightforward.

Most peptides cannot survive the journey through your digestive system. Stomach acid and digestive enzymes break them down into individual amino acids before they reach the bloodstream. You absorb the amino acids, not the peptide. Subcutaneous injection just under the skin bypasses this entirely and delivers the peptide directly into tissue and circulation, intact.

There are exceptions. Semaglutide is available as an oral tablet (Rybelsus), but the dose required is substantially higher than the injectable version because only a small fraction survives digestion. Topical peptides like GHK-Cu only need to penetrate the outer layers of skin to reach their target cells. And oral collagen peptides work by being absorbed as amino acids and then reassembled, rather than entering the bloodstream as intact peptides.

A practical red flag: if a supplier is selling a research peptide as an oral capsule and claiming the same results as an injectable version, that claim deserves careful scrutiny.

Frequently Asked Questions

What are the negatives of taking peptides?

MHRA-licensed peptides like semaglutide, Tirzepatide have well-documented side effects from large clinical trials nausea, digestive discomfort, and in rare cases more serious effects. Research peptides carry a different kind of uncertainty: long-term human safety data simply does not exist yet. Sourcing quality is also a real variable poorly manufactured or contaminated products are a genuine risk in the research peptide space.

Is it safe to take peptides every day?

For MHRA-licensed peptides prescribed by a doctor, daily or weekly use is clinically guided and considered safe within those parameters. For research peptides, there is no established safe daily dosing protocol for humans the honest position is that we do not yet have sufficient human data to answer this definitively.

Are peptides like steroids?

No they are fundamentally different. Steroids are fat-soluble molecules that enter cells directly and alter gene activity broadly throughout the body, which drives their significant systemic side effects. Peptides work from outside the cell via surface receptors and are far more targeted in their action. The mechanisms, risk profiles, and legal status are entirely separate.

What happens when you start taking peptides?

It depends entirely on the peptide. Users of GLP-1 medicines typically notice reduced appetite within days, with meaningful weight changes unfolding over weeks to months. Research peptides used for recovery or tissue repair are generally assessed over 4 to 12 weeks. Peptides work by nudging biological processes effects are gradual, not immediate.

Conclusion

Peptides are not a new invention or a passing trend. They are a fundamental part of how your body communicates with itself and scientists have been studying, synthesising, and refining them for over a century.

What is new is the scale. MHRA-licensed peptide medicines are transforming the treatment of obesity and diabetes. Research peptides are being explored across recovery, longevity, and performance with a level of community-driven engagement the science has never seen before. And the manufacturing and supply chain behind both worlds is more accessible and more variable than ever.

Understanding what peptides are, how they work, and where they come from gives you the foundation to navigate this space clearly. The next step is understanding the evidence behind specific compounds.

Go deeper:

Important: This article is for educational purposes only and does not constitute medical advice. Research peptides are sold in the UK for research purposes only and are not licensed for human therapeutic use. If you are considering any peptide treatment, join our community.
Join our Discord

References

Wang L, et al. Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy. 2022.https://www.nature.com/articles/s41392-022-00904-4
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Henninot A, et al. The Current State of Peptide Drug Discovery. Journal of Medicinal Chemistry. 2018.https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01061
Sikiric P, et al. Multifunctionality of BPC 157. Pharmaceuticals. 2025.https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/
Pickart L, Margolina A. Regenerative and Protective Actions of GHK-Cu. International Journal of Molecular Sciences. 2018.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073405/
NIH StatPearls. Biochemistry, Peptide.https://www.ncbi.nlm.nih.gov/books/NBK562260/